CN116725126A - 溶血磷脂酸在防治猪感染性腹泻中的应用 - Google Patents
溶血磷脂酸在防治猪感染性腹泻中的应用 Download PDFInfo
- Publication number
- CN116725126A CN116725126A CN202310830639.1A CN202310830639A CN116725126A CN 116725126 A CN116725126 A CN 116725126A CN 202310830639 A CN202310830639 A CN 202310830639A CN 116725126 A CN116725126 A CN 116725126A
- Authority
- CN
- China
- Prior art keywords
- piglets
- lysophosphatidic acid
- feed
- intestinal
- diarrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 title claims abstract description 43
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 206010012742 Diarrhoea infectious Diseases 0.000 title claims abstract description 12
- 208000001848 dysentery Diseases 0.000 title claims abstract description 12
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 7
- 241000588724 Escherichia coli Species 0.000 claims abstract description 17
- 239000003674 animal food additive Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229940042126 oral powder Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 229910052740 iodine Inorganic materials 0.000 abstract description 2
- 239000011630 iodine Substances 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 206010012735 Diarrhoea Diseases 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 239000000147 enterotoxin Substances 0.000 description 5
- 231100000655 enterotoxin Toxicity 0.000 description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 5
- 230000000688 enterotoxigenic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000282887 Suidae Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229930182843 D-Lactic acid Natural products 0.000 description 2
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229940022769 d- lactic acid Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091007907 GPCRs class A Proteins 0.000 description 1
- 102000038630 GPCRs class A Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
Abstract
本发明公开了溶血磷脂酸作为饲料添加剂在防治猪感染性腹泻中的应用,属于饲料营养技术领域。溶血磷脂酸是在机体体内能内源性产生一类脂质物质,其可以通过抑制CFTR依赖的碘外流减少仔猪因感染大肠杆菌造成的小肠肠液大量分泌,预防断奶仔猪对大肠杆菌的易感性,有效维护仔猪肠道健康。溶血磷脂酸作为机体内源性的物质,本发明首次发现饲料添加溶血磷脂酸对仔猪大肠杆菌感染性腹泻有防治效果。
Description
技术领域
本发明属于饲料营养技术领域,涉及溶血磷脂酸作为饲料添加剂在防治猪感染性腹泻中的应用。
背景技术
仔猪早期断奶是现代集约化养殖的关键技术之一,能够有效缩短母猪哺乳期,提高母猪年生产力,最大限度发挥母猪繁殖性能。然而早期断奶仔猪在一方面会失去来自母体母乳的被动免疫,会降低仔猪免疫力,使得仔猪易感外源病原致使抗病力下降。另一方面,仔猪在早期断奶时胃肠道并未发育完全,同时断奶后会造成的肠道形态结构发生改变,包括肠道绒毛缩短,隐窝深度增加,消化酶活性降低。这一胃肠道的变化将会影响仔猪对日粮中营养物质的消化吸收,未消化的营养物质在进入肠道后端发酵后易被致病菌利用繁殖,降低肠道有益菌数量,增加有害菌数量,使得肠道生物屏障受损。同时当仔猪肠道内通透性增大,肠道内外源病原可以轻易通过肠道上皮细胞侵入机体,诱发仔猪出发肠道炎症、腹泻等症状。
根据大肠杆菌在感染过程中能否产生肠毒素的能力,可将大肠杆菌分为产肠毒素大肠杆菌和非产毒素大肠杆菌两大类。产肠毒素大肠杆菌(ETEC)是一类最常见的引起畜禽肠道疾病的病原微生物,也是造成仔猪死亡的重要因素之一。ETEC依靠粘附因子定植于宿主肠上皮细胞,大量增殖后破坏肠道微生态平衡引发继发性感染,同时分泌肠毒素使得肠道上皮细胞渗透压失衡,从而损伤肠道屏障功能,引起肠道功能紊乱,导致仔猪腹泻,脱水,甚至死亡。ETEC感染仔猪肠道首先会通过黏附素与宿主肠道上皮相结合。目前,研究较多的动物源ETEC黏附素主要有K88(F4)、K99(F5)、987P(F6)等,其中以K88(F4)最受关注。K88主要包括K88ab、K88ac、K88ad三种血清型,K88ac被认为是引起仔猪腹泻的主要血清型,由ETEC K88ac感染仔猪肠上皮细胞(IPEC-J2)所导致的免疫反应最明显。ETEC在小肠定植后会大量增殖并分泌与腹泻直接相关的毒力因子肠毒素,包括不耐热肠毒素(LT)和耐热肠毒素(ST)2种。猪源ETEC分泌的耐热肠毒素(ST)可与猪肠道上皮细胞的鸟苷酸环化酶C(GC-C)的胞外域和硫脂受体相结合,导致肠内水盐代谢失衡,大量水分和电解质外渗,引起分泌性腹泻。
在生产上,当仔猪出现大肠杆菌感染性腹泻时,常会采用抗生素对仔猪进行治疗。但抗生素在治疗腹泻疾病的同时会造成畜禽免疫力的降低、细菌耐药性增加、存在药物残留以及致基因突变、引发畸形和诱发癌症等毒副作用。
溶血磷脂酸(LPA)是一种在血清中浓度较高,但在其他真核生物组织中的浓度较低的具有生物活性的甘油磷脂。LPA已知有至少六个高亲和力、同源型视紫红质样G-蛋白偶联受体,以及一个核受体及过氧化物酶体增殖物激活受体C(PPARc)。LPA的生物学作用可以分为三大类:一是正常细胞功能,比如平滑肌收缩、细胞自身趋化性、Ca2+动员和神经递质释放、血小板聚集、红细胞生成、骨髓基质的造血功能、细胞正常增殖和迁移、细胞分化等;二是抑制各种病症,包括精神分裂、动脉粥样硬化、异常瘙痒、哮喘、纤维化、生殖障碍和骨代谢;三是调节很多癌细胞系恶性能力的获得,比如癌细胞的异常增殖和迁移、侵染、自噬、抗药性等能力。
发明内容
本发明的目的在于提供溶血磷脂酸作为饲料添加剂在防治猪感染性腹泻中的应用,溶血磷脂酸(1-油酰基-sn-甘油3-磷酸钠),分子量510.39,结构如下:
优选地,所述猪感染性腹泻是由大肠杆菌引起的。
更优选地,所述饲料添加剂为粉剂、颗粒剂。
更优选地,所述饲料添加剂为含有有效剂量溶血磷脂酸的组合物或混合物。
更优选地,所述饲料添加剂组合物为溶血磷脂酸和载体混合制成的预混剂。
更优选地,所述溶血磷脂酸预混剂在饲料中的添加剂量为饲料总重量的0.1%~0.5%。
与现有技术相比,本发明具有如下有益效果:
溶血磷脂酸是在机体体内能内源性产生一类脂质物质,其可以通过抑制CFTR依赖的碘外流减少仔猪因感染大肠杆菌造成的小肠肠液大量分泌,同时起到预防断奶仔猪对大肠杆菌的易感性,有效维护仔猪肠道健康。溶血磷脂酸作为机体内源性的物质,本发明首次发现饲料添加溶血磷脂酸对仔猪大肠杆菌感染性腹泻有防治效果,且无毒副作用,动物排泄物对环境无污染。
具体实施方式
实施例1
1.试验材料
25日龄DLY断奶仔猪,平均体重(7.24±0.07)kg。
2.试验设计
试验选用32头仔猪,分为4组,每组8个重复,试验期为21天。ETEC+LPA组和LPA组日粮添加0.3%的溶血磷脂酸,试验第18天对照组和LPA组灌喂500ml的生理盐水,ETEC组和ETEC+LPA组仔猪灌喂500ml ETEC菌液,ETEC浓度为1×109CFU浓度。具体分组见表1。试验21天早上进行屠宰采样。
表1试验分组
3.试验结果
3.1溶血磷脂酸对仔猪大肠杆菌感染性腹泻率的影响
如表2所示,ETEC攻毒显著提高了仔猪腹泻率和腹泻指数(P<0.05)。饲料中添加LPA的可显著改善由ETEC引起的仔猪腹泻,显著降低仔猪腹泻率(P<0.05)和腹泻指数(P<0.05)。
表2饲料中添加LPA对攻毒后仔猪腹泻指标的影响
注:同行数据肩标无字母或相同字母表示差异不显著(P>0.05),不同小写字母表示差异显著(P<0.05)。下表同。
3.2溶血磷脂酸对仔猪感染大肠杆菌肠道组织形态的影响
如表3所示,CON组与LPA组的绒毛高度、隐窝深度、绒毛高度/隐窝深度比值(V/C)无显著性(P>0.05)。ETEC攻毒降低十二指肠和回肠的绒毛高度和V/C(P<0.05),提高了回肠的隐窝深度(P<0.05)。饲料中添加LPA显著提高ETEC攻毒仔猪十二指肠和回肠的绒毛高度和V/C(P<0.05)。此外,LPA降低ETEC攻毒仔猪回肠隐窝深度并提高绒隐比(P<0.05)。
表3饲料中添加LPA对仔猪肠道组织形态的影响
3.3溶血磷脂酸对仔猪感染大肠杆菌肠道通透性的影响
如表4所示,与CON组相比,ETEC攻毒仔猪LPS、DAO、D-乳酸、流体聚集率显著上升(P<0.05),饲料添加LPA显著降低ETEC攻毒仔猪的LPS、DAO、D-乳酸、流体聚集率(P<0.05)。
表4饲料中添加LPA对攻毒后仔猪通透性的影响
4.结论
溶血磷脂酸对仔猪生长性能无显著负面影响,可显著改善ETEC造成的仔猪肠道组织形态的损伤和通透性的降低,可显著降低仔猪大肠杆菌引起的腹泻率。
实施例2
1.试验材料
21日龄DLY断奶仔猪,平均体重(6.23±0.82)kg。
2.试验设计
试验选用24头仔猪,分为3组,每组8个重复,试验期为21天。ETEC+LPA组日粮添加0.2%的溶血磷脂酸,试验第18天对照组灌喂200ml的生理盐水,ETEC组和ETEC+LPA组仔猪灌喂200mlETEC菌液,ETEC浓度为1×109CFU浓度。具体分组见表5。试验21天早上进行屠宰采样。
表5试验分组
3.试验结果
如表6所示,攻毒前添加溶血磷脂酸可显著降低腹泻率(P<0.05),同时攻毒后,添加溶血磷脂酸的大肠杆菌攻毒仔猪腹泻率和腹泻指数也显著下降(P<0.05)。
表6仔猪大肠杆菌腹泻率
4.结论
饲料添加0.2%溶血磷脂酸可有效降低断奶仔猪大肠杆菌引起的腹泻率。
以上所述的实施例仅是对本发明的优选方式进行描述,并非对本发明的范围进行限定,在不脱离本发明设计精神的前提下,本领域普通技术人员对本发明的技术方案做出的各种变形和改进,均应落入本发明权利要求书确定的保护范围内。
Claims (6)
1.溶血磷脂酸作为饲料添加剂在防治猪感染性腹泻中的应用。
2.根据权利要求1所述的应用,其特征在于,所述猪感染性腹泻是由大肠杆菌引起的。
3.根据权利要求1或2所述的应用,其特征在于,所述饲料添加剂为口服粉剂或颗粒剂。
4.根据权利要求1或2所述的应用,其特征在于,所述饲料添加剂为含有有效剂量溶血磷脂酸的组合物或混合物。
5.根据权利要求4所述的应用,其特征在于,所述饲料添加剂组合物为溶血磷脂酸和载体混合制成的预混剂。
6.根据权利要求5所述的应用,其特征在于,所述溶血磷脂酸预混剂在饲料中的添加剂量为饲料总重量的0.1%~0.5%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310830639.1A CN116725126A (zh) | 2023-07-07 | 2023-07-07 | 溶血磷脂酸在防治猪感染性腹泻中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310830639.1A CN116725126A (zh) | 2023-07-07 | 2023-07-07 | 溶血磷脂酸在防治猪感染性腹泻中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116725126A true CN116725126A (zh) | 2023-09-12 |
Family
ID=87916902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310830639.1A Pending CN116725126A (zh) | 2023-07-07 | 2023-07-07 | 溶血磷脂酸在防治猪感染性腹泻中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116725126A (zh) |
-
2023
- 2023-07-07 CN CN202310830639.1A patent/CN116725126A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9011836B2 (en) | Methods of treating pigs with Bacillus strains | |
Wu et al. | Effects of the antimicrobial peptide cecropin AD on performance and intestinal health in weaned piglets challenged with Escherichia coli | |
McDonnell et al. | The effect of dietary laminarin and fucoidan in the diet of the weanling piglet on performance, selected faecal microbial populations and volatile fatty acid concentrations | |
CN102304489B (zh) | 一株罗伊氏乳杆菌及其应用 | |
CN112618579B (zh) | 一种防治仔猪腹泻复合益生菌制剂和制备方法及应用 | |
CN103525718B (zh) | 一种蜡状芽孢杆菌及其益生菌粉及该菌粉的制备和用途 | |
CN104206789A (zh) | 一种用于预防奶牛乳房炎和布鲁氏菌病的饲料添加剂及其制备方法 | |
CN105325708A (zh) | 用于脱霉和治疗腹泻的无抗饲料添加剂及制备方法和应用 | |
CN110692863A (zh) | 一种提高罗非鱼保肝护肠能力的植物提取物饲料添加剂 | |
Jonsson et al. | Establishment in the piglet gut of lactobacilli capable of degrading mixed‐linked β‐glucans | |
Wu et al. | Effect of glutamine on the intestinal function and health of broilers challenged with Salmonella pullorum | |
Smith et al. | The influence of streptomycin and streptothricin on the intestinal flora of mice | |
CN114521610A (zh) | 一种新型水溶性生物解霉剂及其使用方法和应用 | |
CN110200156A (zh) | 一种提高采食量的仔猪混合型饲料添加剂及应用 | |
Hampson et al. | 69 Dietary Manipulation of Enteric Disease | |
CN116790402B (zh) | 一株具有抗炎特性的单形拟杆菌菌株、培养方法及应用 | |
CN116725126A (zh) | 溶血磷脂酸在防治猪感染性腹泻中的应用 | |
CN111000052A (zh) | 一种仔猪酶菌饲料添加剂及其应用 | |
JP7092785B2 (ja) | 飼料添加物製剤ならびにその製造方法および使用方法 | |
CN106720939A (zh) | 一种复合乳酸菌微生态饲料添加剂及其应用 | |
Pluske et al. | Nutritional management of the gastrointestinal tract to reduce enteric diseases in pigs | |
Belenguer et al. | Effect of the source and level of cereal in diet on the rabbit caecal environment and microbial population | |
US8927565B2 (en) | Compositions for veterinary and medical applications | |
CN112262926A (zh) | 一种氧化锌肠溶缓释微丸及其制备方法、包含其的饲料组合物 | |
DE69626200T2 (de) | Inhibierung von c. difficile-infektionen mit unverdaulichen oligosacchariden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |